Pharmaceuticals, Biotechnology & Life Sciences

Lisata Therapeutics boosts governance with finance veteran Jeffrey Farrow, aiming to drive growth in Phase 2b programs while navigating investor caution and recent volatility.

iBio insider option grants signal confidence amid a 34% stock decline – insiders lock in upside, aligning interests with investors.

ORUKA Therapeutics insider buying sparks bullish signals, contrasting with heavy selling—insightful for investors eyeing its cardiology pipeline.

Oncolytics insiders shift gears: Wang Xiaodong’s mix of sales and a low‑price buy signals confidence ahead of Cohort‑5 data, hinting at undervalued upside.

Insider trades by Nurix’s chief scientist reveal routine liquidity, not market signals – a balanced plan that keeps executive and investor interests aligned.

ADAR1 Capital’s surge in InMed shares signals bullish confidence in the cannabis‑based biotech pipeline—watch for a potential rally amid micro‑cap volatility.

Rothblatt’s latest 10b‑5‑1 trade shows steady confidence in United Therapeutics—buying 9,500 shares amid balanced insider activity, signaling long‑term belief in the company’s growth.

Insider buys at Alaunos Therapeutics signal confidence as the company acquires Velaris, promising new cardiopulmonary assets and upside for long‑term investors.

Insightful Alector insider moves: key exec buys and option repricing signal confidence in neuro‑degeneration pipeline and potential rebound.

Regeneron insider trading reveals Andrew Murphy’s strategic buy‑sell plan, showing confidence in the biotech firm’s strong pipeline and market growth.